CTOs on the Move

Alkermes

www.alkermes.com

 
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.alkermes.com
  • 852 Winter Street
    Waltham, MA USA 02451
  • Phone: +353 1 772 8000

Executives

Name Title Contact Details
Jonathan Brooks
Senior Director, Global Security Profile
John Lamoureux
Senior Director of Information Technology Profile
Mike Legato
Associate Director of Information Technology Applications Profile

Similar Companies

Wyandot

Wyandot BHN is a family of organizations providing comprehensive behavioral health solutions to Wyandotte County, Kansas and the greater Kansas City metro.

Corepharma LLC

Corepharma LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Regulatory Affairs Professionals Society

RAPS is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products.

Cerebral

At Cerebral, we`re on a mission to democratize access to high-quality mental health care. We believe that everyone everywhere deserves to get the care they need, and are striving to make care convenient and accessible, while tackling the stigmas that surround mental illness. Since launching in January 2020, we have gone from a team of 5 to over 4,000 across the United States. With support from investors like SoftBank, Silver Lake, Access Industries, Bill Ackman, WestCap, and others, and impactful leaders like you, we`ll continue to democratize mental health care and double down on clinical quality and deliver exceptional patient outcomes for years to come. With a heavy focus on clinical quality and safety in all that we do, we`ve accomplished excellent patient outcomes: • 82% of patients report an improvement in their anxiety symptoms after using Cerebral. • 75% of patients who report improvement in their depression see improvement within 60 days. • 50% of patients who initially report suicidal ideation no longer harbor suicidal thoughts after treatment with Cerebral. This is just the beginning for Cerebral, and we won`t stop building, growing, and iterating until everyone, everywhere can access high-quality evidence-based mental health care without high costs and/or long wait times. We`re looking for mission-driven leaders who share these values, and we need your help as we transform access to high-quality mental health care in the United States and beyond.